Comparison 7. Fondaparinux versus LMWH sensitivity analysis without EFFORT.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 total VTE	10	9141	Risk Ratio (M‐H, Random, 95% CI)	0.55 [0.41, 0.73]
2 symptomatic VTE	8	12042	Risk Ratio (M‐H, Fixed, 95% CI)	1.03 [0.65, 1.63]
3 total DVT	9	9158	Risk Ratio (M‐H, Random, 95% CI)	0.53 [0.40, 0.71]
4 proximal DVT	8	8163	Risk Ratio (M‐H, Random, 95% CI)	0.56 [0.31, 1.03]
5 total PE	9	12152	Risk Ratio (M‐H, Fixed, 95% CI)	1.24 [0.65, 2.34]
6 fatal PE	8	10909	Risk Ratio (M‐H, Fixed, 95% CI)	0.72 [0.25, 2.05]
7 non‐fatal PE	8	10909	Risk Ratio (M‐H, Fixed, 95% CI)	1.40 [0.63, 3.11]
8 major bleeding	10	12303	Risk Ratio (M‐H, Fixed, 95% CI)	1.38 [1.09, 1.75]
9 fatal bleeding	5	10095	Risk Ratio (M‐H, Fixed, 95% CI)	0.71 [0.14, 3.62]
10 MI	6	10720	Risk Ratio (M‐H, Fixed, 95% CI)	1.28 [0.69, 2.37]
11 all causes of death	10	12202	Risk Ratio (M‐H, Fixed, 95% CI)	0.88 [0.63, 1.22]
12 death associated with VTE or bleeding	5	4774	Risk Ratio (M‐H, Fixed, 95% CI)	0.89 [0.38, 2.07]
13 other serious adverse effects	9	12267	Risk Ratio (M‐H, Fixed, 95% CI)	1.06 [0.95, 1.20]